Announcement
10 Oct 2025
In October 2025, the United States of America announced an agreement with AstraZeneca to implement most-favoured-nation drug pricing for America patients. The agreement also includes a three-year delay on Section 232 tariffs for AstraZeneca.
Source
Sign in to access
Number of interventions
3
3 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
31 Jul 2026
Revocation date:
20 Jan 2029
Updated: 13 Oct 2025
Local operations incentive
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Updated: 13 Oct 2025
Tax or social insurance relief
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Updated: 13 Oct 2025
Import tariff
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.